- Origin Therapeutics Holdings (ORIG) announced the election of Michael Galego as a director of the company
- Galego is an executive, lawyer and corporate director with extensive M&A, corporate finance and governance experience
- He has been the co-founder of several businesses, including ICC Labs, Terrace Global and several other TSXV listed companies
- Origin Therapeutics is an actively managed investment issuer focusing on making equity investments in psychedelics industry-related companies
- Origin Therapeutics Holdings Inc. (ORIG) opened trading at C$0.05 per share
Origin Therapeutics Holdings (ORIG) has appointed Michael Galego as a director of the company.
Galego is an executive, lawyer and corporate director with extensive M&A, corporate finance and governance experience. He is currently the CEO of Apolo Capital Advisory Corp. and sits on the board of directors of several public and private companies.
He has co-founded several businesses, including ICC Labs, Terrace Global, and other TSXV-listed companies. Galego was the CEO of the Stronach Group, Agricultural Division and an advisor to Mr. Frank Stronach. He also served as the legal counsel to several public and private companies operating in the resource sector in South America.
Galego was previously legal counsel to Pacific Rubiales Energy Corp., CGX Energy Inc., Medoro Resources Corp., Alange Energy Inc., and Gran Colombia Corp. He was involved in more than $3 billion in equity transactions and more than $5 billion in debt financings. Galego was a co-founder and director of ICC Labs until its sale to Aurora Cannabis Inc. in November 2018.
Galego holds an LLB. From the University of Windsor and a B.A. from York University. He is also a graduate of the Harvard Business School High Potentials Leadership Program and was named to Lexpert’s “Top 40 under 40”.
Origin Therapeutics is an actively managed investment issuer focusing on making equity investments in psychedelics industry-related companies.
Origin Therapeutics Holdings Inc. (ORIG) opened trading at C$0.05 per share.